The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.

Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.

Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.

1. HIV is a Virus; AIDS is a Syndrome

HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.

AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.

2. Not Everyone with HIV Develops AIDS

A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.

Without treatment, however, HIV progresses through three stages:

- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.

- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.

- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.

3. HIV is Transmissible; AIDS is Not

Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.

AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.

4. Diagnosis Methods Differ

HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.

AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.

5. Treatment Goals Are Different

The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.

For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.

Role of Community Engagement in Combatting HIV/AIDS

While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."

Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.

The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.

Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.

Climate change and rapid urbanization are changing mosquito habitats, and shifting dengue serotypes are reshaping the disease landscape in India. As a result, the country is now witnessing a transformation in how dengue spreads, who it affects, and how severe infections can become.

Once considered a seasonal monsoon illness, dengue is now increasingly becoming a year-round public health challenge, extending into hill states, semi-urban regions, and previously low-risk geographies.

In an exclusive interview with HealthandMe, Dr. Shikha Taneja Malik, Senior Scientific Affairs Manager, Drugs for Neglected Diseases initiative (DNDi), South Asia, discussed why India’s dengue numbers are likely being massively undercounted, how surveillance and diagnostic gaps are masking the real scale of the crisis, and why young adults are facing more severe infections due to changing serotypes.

Dr. Shikha also explained the urgent global push for affordable therapeutics and the challenges India still faces in developing an indigenous dengue vaccine despite its strong manufacturing capacity.

Here are the excerpts from the interview:

Q. Dengue was always called a monsoon disease. Is that label now dangerously misleading?

Dr. Shikha: Yes, I would argue that labels are not just outdated but risky, too. What we are seeing across India and across the region is a fundamental shift in the transmission pattern.

Dengue used to follow a fairly predictable seasonal curve — cases would spike between July and November, track the monsoon, and then recede. That curve is flattening. We are now seeing cases in February, March, and May — months that were previously considered safe. Delhi, Mumbai, Bengaluru — cities that used to have clear off-seasons for dengue — are reporting year-round transmission.

Warmer temperatures, altered rainfall patterns, unplanned urbanization, and poor sanitation have lengthened transmission seasons, making dengue a year-round systemic crisis. Models now predict year-round transmission in coastal regions, though monsoon months will retain the highest peak.

Also read: National Dengue Day 2026: India Reports 6,927 Cases And 10 Deaths In 2026

Q. Are serotype shifts driving changing dengue patterns, especially in young adults?

Dr. Shikha: Yes, India is witnessing active serotype shifts, and they directly explain rising severity, especially in young adults. Initial infection with one of the four dengue serotypes results in lifelong immunity to that specific serotype. Whereas, a secondary infection with a different serotype can trigger Antibody-Dependent Enhancement (ADE).

Young adults who were exposed to one serotype in childhood are now encountering a new dominant serotype, making them especially vulnerable to severe secondary infections.

Q. Is India undercounting dengue cases? Why do so many cases go unreported?

Dr. Shikha: The 2.89 lakh figure in 2023 is what our surveillance system captures, but it is almost certainly a fraction of the true burden. The Lancet has estimated that India accounts for around 33 per cent of the global dengue burden, and globally, we are looking at approximately 400 million infections every year. That puts India's real annual dengue burden potentially in the tens of millions — not hundreds of thousands.

Few studies have shown that the estimates of actual cases are approximately 282 times higher.

There are several reasons why cases go unreported, and they compound each other.

• A large proportion of infections are either asymptomatic or present as a generic fever — patients never seek formal care.
• Our surveillance system is passive and fragmented. Reporting is largely dependent on public health facilities.
• Confirmatory testing through NS1 antigen tests or PCR requires infrastructure that is not yet uniformly available at the primary health center level, particularly in rural and semi-urban areas.

Q. Are previously dengue-free regions in India now reporting cases due to climate change?

Dr. Shikha: Yes, the geographic spread is both significant and well-documented. Climate change is playing a major role in this shift. Rising temperatures, changing rainfall patterns, increasing humidity, and rapid unplanned urbanization are creating more favorable conditions for Aedes aegypti mosquitoes to survive and transmit the virus for longer periods each year.

Since the mid-1990s, dengue has rapidly spread to regions where it was historically non-existent, including Odisha, Arunachal Pradesh, and Mizoram. In the early 2000s, dengue was endemic only in a few southern and northern states; it has since spread to many states, including union territories.

Read More: Ebola Outbreak: Rare Bundibugyo Strain Confirmed In DR Congo And Uganda

The shift is particularly visible in hilly and cooler geographies such as Himachal Pradesh and Jammu & Kashmir. Climate modelling projects further expansion of Aedes albopictus into upper Himalayan regions, including Leh-Ladakh and Arunachal Pradesh, by 2050.

Q. What are the biggest challenges in indigenous dengue vaccine production in India?

Dr. Shikha: India has strong vaccine manufacturing capacity, but dengue remains scientifically complex. Existing vaccines have limitations and do not cover all vulnerable groups.

India’s first Phase 3 trial for an indigenous dengue vaccine, DengiAll, is underway across 18 states. The Butantan vaccine candidate, originally developed by NIH, has been licensed to Indian companies, including Panacea, SIIPL, and Indian Immunologicals, with the ICMR-Panacea candidate being the most advanced.

The recent DCGI approval of Qdenga is encouraging, but sustained financing and coordination between ICMR, DBT, and industry will be critical for developing a truly indigenous vaccine.

Dengue has become one of the fastest-emerging health crises in the urban parts of India. Every year during the monsoon season, the number of dengue cases rises dramatically in many Indian cities, posing a huge burden on the healthcare sector.

Though climate and mosquitoes are usually cited as reasons for the surge in dengue cases, the problem actually lies in how urban life and the infrastructure of the cities have changed over the decades.

Why Urban Areas Are More Vulnerable

The dengue virus is spread through the Aedes aegypti mosquito that lives well in fresh still water, which is abundant in urban areas.

Mosquitoes breed in construction sites, open water tanks, old plastic buckets, flower pots, coolers, water stored on roofs, and blocked drainage systems. Due to the growing size of cities and high population density, mosquito-borne diseases have become more common.

There are many factors that contribute to the rise in the number of dengue patients, one of which is unplanned city expansion. The fast pace of development in the cities results in stagnant water in the construction areas going unnoticed for weeks.

Moreover, improper drainage and a lack of sanitation facilities help mosquitoes breed. Even posh societies and offices can suffer if proper checks are not conducted.

Urban lifestyle trends also act as indirect factors contributing to the issue. Longer working hours, higher levels of indoor activities, and reliance on mechanical ventilation lead to less focus on environmental hygiene issues.

Families tend to take mosquito prevention steps only after an outbreak starts. The overuse of plastics and poor waste management practices in urban areas have exacerbated waterlogging problems.

The situation has been exacerbated by climate change and global warming. Mosquitoes can breed at a faster pace and survive for a longer period of time in the warm climate and unpredictable rain patterns. Another factor that plays an important role is urban heat islands, which refer to places that are hotter because of man-made concrete buildings.

What Needs to Change?

In order to curb the incidence of dengue, there must be an all-around transformation, both on the part of the governing authorities and the people. Firstly, urban planning should take into consideration good drainage facilities, frequent fogging, garbage disposal services, and proper regulation of building sites. Secondly, there must be frequent checks in residential areas, schools, offices, markets, and open public areas.

Secondly, the awareness campaign needs to be practical and more community-oriented. The citizens should realize that the prevention of dengue starts from their homes. Actions like washing the coolers once a week, covering the water tank, not allowing the water to stagnate, and using mosquito repellents will go a long way in minimizing the spread of dengue.

Early Detection and Healthcare Preparedness

Healthcare preparedness is also equally important. The early detection and proper treatment of dengue could help avoid any serious complications. One should never overlook symptoms like fever, body pain, headache, rashes on the skin, nausea, and weakness during the rainy season.

Combatting dengue fever is no longer just a matter of health care but rather a question of urban planning and lifestyle issues. As the cities continue to expand, everyone should unite and come up with healthier and more environmentally friendly cities. Otherwise, we may see more recurring problems of dengue outbreaks in urban settings every year.

Amid growing discussions around hantavirus transmission through body fluids, experts today stressed that cases involving transmission through breast milk or semen remain extremely rare and should not trigger unnecessary panic.

The discussions began after a 2023 study published in the journal Viruses found that the Andes strain of the rat-borne virus can persist in human semen for up to six years.

More concerning was the possibility that the virus could potentially be transmitted sexually even after a person has recovered, according to the peer-reviewed study.

The research, conducted by Swiss scientists at Spiez Laboratory, suggested that hantavirus may survive in the male reproductive tract like viruses such as Ebola.

“Taken together, our results show that the Andes virus has the potential for sexual transmission,” the study said. However, to date, no confirmed case of such transmission has been documented.

Why Viral RNA Can Persist In Semen

Speaking to HealthandMe, Dr. Rajeev Jayadevan, convenor of the IMA research cell, explained that the detection of Andes virus RNA — the hantavirus strain linked to the recent MV Hondius cruise ship outbreak — in semen long after recovery is not entirely unexpected.

“The finding of RNA belonging to the Andes virus in human semen long after recovery is no surprise. In fact, this is a well-described scenario in at least 27 different viruses, including Zika and Ebola,” he said.

He explained that viruses reaching the testis enter what is known as an “immune-privileged” site protected by the blood-testis barrier (BTB).

“The testis is naturally shielded from the body’s immune system to protect newly formed sperm cells from being recognised and destroyed as ‘foreign’,” Dr. Rajeev said.

According to the expert, many viruses take advantage of this natural immune protection, allowing them to remain in the area longer than expected.

However, he clarified that although researchers detected viral RNA in semen, the virus itself could not be cultured, meaning there is no proof that the infectious virus remained present.

Also read: Ebola Outbreak: Rare Bundibugyo Strain Confirmed In DR Congo And Uganda

Can Hantavirus Spread Via Breast Milk?

Another study published in Emerging Infectious Diseases, a monthly open-access peer-reviewed medical journal published by the US Centers for Disease Control and Prevention, highlighted the risk of mother-to-child transmission of the Andes strain of hantavirus through breast milk.

Andes virus (ANDV) is the only hantavirus known to spread between humans through close contact.

“We detected the genome and proteins of ANDV in breast milk cells from an infected mother in Chile who transmitted the virus to her child, suggesting gastrointestinal infection through breast milk as a route of ANDV person-to-person transmission,” the study said.

Epidemiologist Dr. Amitav Banerjee, professor at DY Patil Vidyapeeth, Pune, told HealthandMe that while isolated cases of hantavirus transmission from mother to child through breast milk have been reported, they are highly uncommon.

“These cases of hantavirus transmission through breast milk from mother to child are very rare. As a general rule, there is no need to worry excessively,” he said.

According to him, mothers experiencing fever during the acute stage of illness may temporarily avoid breastfeeding because viral load tends to be highest during active infection and just before symptoms appear. However, he stressed that breastfeeding should not be stopped routinely out of fear.

Dr. Amitav explained that the situation is somewhat comparable to HIV transmission through breast milk, which also occurs in less than 1 percent of cases. Despite that, mothers in many developing countries are still advised to continue breastfeeding because the health risks of depriving infants of breast milk are often greater than the risk of viral transmission.

He noted that hantavirus differs significantly from HIV because it is generally an acute and transient infection, unlike HIV, which persists lifelong in body fluids.

“Hantavirus infection is acute and transient, whereas HIV is lifelong,” he said, adding that hantavirus usually clears from the body after recovery, including from semen and other body fluids.

Sexual Transmission After Recovery Still Unclear

Dr. Rajeev noted that the Andes virus spreads primarily through close contact and shared personal space while a patient is symptomatic.

“Whether it can be sexually transmitted long after recovery remains unknown,” he said.

Overinterpreting RT-PCR Results

Dr. Amitav also cautioned against overinterpreting isolated reports of viral detection in semen or breast milk.

According to him, RT-PCR tests are extremely sensitive and may detect dead viral particles even after the infection has resolved. Therefore, a positive RT-PCR result does not necessarily mean that a person remains infectious.

“In fact, RT-PCR is highly sensitive and often used more for research and surveillance purposes. Detecting viral material does not always indicate active infection or transmission risk,” he said.

He added that hantavirus does not appear to persist as an infectious virus for a long period after recovery and that there is currently no strong evidence supporting long-term transmission once a patient has recovered.